The Parker Institute sponsors several immunotherapeutic clinical trials. These are the PICI trials currently open for accrual at MSKCC.
-
PICI0044/ NCT04787991
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION) -
NCT04374461
Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients with Refractory COVID-19 Infection -
NCT04426201
Recombinant Human Interleukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic Patients with COVID-19 Infection (COVID) -
PICI0025
An Exploratory Study of Nivolumab with or without Ipilimumab Immunotherapy According to Tumor CD8 Level in Patients with Advanced Cancer -
PICI0001
A Phase II Study of Immunotherapy: Ipilimumab Alone or with Nivolumab in Patients Whose Melanoma Continues to Grow Despite Nivolumab or Pembrolizumab -
PICI0002
A Phase IB/II Study of APX005M Immunotherapy plus Gemcitabine and nab-Paclitaxel, with or without Nivolumab, in Patients with Previously Untreated Metastatic Pancreatic Cancer -
PICI0014
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) -
PICI0033
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)